Alemtuzumab is now approved in England (from 28 May 2014) andScotland (7 July 2014) as a treatment for adults with active relapsingremitting multiple sclerosis on the NHS (with funding approved by NHSEngland on 9 September 2014). This liberal approval represents asignificant change in the way drugs for multiple sclerosis are approved;responsibility for deciding who gets alemtuzumab is being handed over topatients and their doctors. People with relapsing-remitting multiplesclerosis now have the option of an aggressive therapy early in theirillness. This is not for everyone, and we urge caution on the behalf ofdoctors and patients considering alemtuzumab treatment. But we arepleased this is now an option.Alemtuzumab is now also licensed in Canada, Argentina, Australia, Braziland Mexico. On November 14th 2014, it was also licensed in the US for“patients who have had an inadequate response to two or more drugsindicated for the treatment of MS”. See here.For our latest publication on the long-term effects of alemtuzumab, seehere.
Trials in multiple sclerosis
We are no longer recruiting for our trial of alemtuzumab and palifermin inrelapsing-remitting multiple sclerosis (”CAMTHY”). An interim analysisfailed to show a benefit of palifermin. (More information on this trial canbe found here: for people with multiple sclerosis;for doctors)I am pleased to say that NHS England have finally agreed to fund the NHScosts of bexarotene as a potential remyelinating agent in multiple sclerosis.I will post more information when we are ready to start.Alasdair ColesFebruary 2016
“We are very pleased to beable to recommendalemtuzumab for adults withrelapsing-remitting multiplesclerosis. Evidence hasshown that alemtuzumab ismore effective and lessexpensive than currentsimilar treatments for thosewith severe relapsing-remitting MS. The NICECommittee heard fromclinical specialists andpatients during the appraisalprocess who describedalemtuzumab as arevolutionary treatment forsome people, allowing themto live their lives as theyhad before their diagnosis.”Sir Andrew Dillon, NICEChief Executive28 May 2014